Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation bead treatment targets Hard-to-Treat pancreatic tumors

NCT ID NCT07595835

Disease control Sponsor: M.R. Meijerink Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to deliver radiation directly into pancreatic tumors using tiny radioactive beads. It is for people with locally advanced pancreatic cancer that has not spread but cannot be removed by surgery. The goal is to see if this approach is safe and feasible, and whether it can help control the tumor while continuing standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \>90 degrees or venous involvement \>270 degrees. * At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\* * Capable of providing written and oral informed consent * Candidate for RNT, judged by a multidisciplinary tumor board * WHO 0-2 Exclusion Criteria: * Eligibility for resection * Participation in other trials focussing on different ablative treatment modalities such as radiofrequency ablation or irreversible electroporation for LAPC * Known hypersensitivity to silicon or phosphor * Bleeding disorders which cannot be corrected with medication * Inability/unwillingness to interrupt anticoagulation therapy * Pregnancy * Metastatic pancreatic cancer * Epilepsy episode(s) in the past six months * Longest tumor diameter \>70 mm or total target tumor volume \>110 ml * Presence of multiple collateral vessels surrounding or adjacent to the target tumor on radiologic imagining, prohibiting safe injection of the OncosilTM device * Presence (or significant risk) of varices near the target tumor on radiologic imaging * Recent clinically significant pancreatitis * Previous administration of radiotherapy to the pancreas

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC - Location VUmc

    RECRUITING

    Amsterdam, North Holland, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.